Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
Mary Lynn Davis-Ajami,1 Jun Wu,2 Katherine Downton,3 Emilie Ludeman,3 Virginia Noxon4 1Organizational Systems and Adult Health, University of Maryland School of Nursing, Baltimore, MD, USA; 2South Carolina College of Pharmacy, University of South Carolina, Greenville, SC, USA; 3Health Sciences and...
Guardado en:
Autores principales: | Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/000e287396fa4c429cff4d0b97cbb272 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir KM, et al.
Publicado: (2016) -
Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes
por: Conway BN, et al.
Publicado: (2018) -
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019) -
Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
por: Valliant A, et al.
Publicado: (2013) -
Chronic Kidney Disease Related Anemia- A Narrative Review
por: Martina Hrvačić, et al.
Publicado: (2021)